Elicio Therapeutics (ELTX) Current Deferred Revenue (2020 - 2025)

Elicio Therapeutics has reported Current Deferred Revenue for 6 years, with the latest figure at $680000.0 in Q1 2025.

• For the quarter ending Q1 2025, Current Deferred Revenue rose 8.45% year-over-year to $680000.0; the trailing twelve-month figure through Mar 2025 stood at $680000.0 (up 8.45% YoY), and the FY2024 full-year result was $1.2 million, up 68.44% from the prior year.
• Current Deferred Revenue for Q1 2025 stood at $680000.0, down from $1.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $5.2 million in Q2 2021, with the low at $400000.0 in Q2 2024.
• Historically, Current Deferred Revenue has averaged $1.9 million across 5 years, with a median of $1.3 million in 2022.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue plunged 82.78% — and 2024, when it jumped 68.44%.
• Elicio Therapeutics' Current Deferred Revenue stood at $2.3 million in 2021, then tumbled by 37.59% to $1.4 million in 2022, then tumbled by 51.67% to $694000.0 in 2023, then jumped by 68.44% to $1.2 million in 2024, then plunged by 41.83% to $680000.0 in 2025.
• The last three Current Deferred Revenue figures came in at $680000.0 (Q1 2025), $1.2 million (Q4 2024), and $400000.0 (Q2 2024), per Business Quant data.